These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
107 related articles for article (PubMed ID: 11753281)
1. Heparin in hypertriglyceridemia: friend or foe? Ng D J Lab Clin Med; 2001 Dec; 138(6):356-8. PubMed ID: 11753281 [No Abstract] [Full Text] [Related]
2. [Low-molecular-weight heparins versus unfractionated heparin for treatment of hemodialysed patients]. Kes P; Basić-Jukić N; Jurić I Lijec Vjesn; 2007; 129(8-9):305-8. PubMed ID: 18198633 [No Abstract] [Full Text] [Related]
3. New anticoagulant drugs: a critical perspective. Haas S Curr Hematol Rep; 2005 Sep; 4(5):335-8. PubMed ID: 16131432 [No Abstract] [Full Text] [Related]
4. Management of thromboembolism in pregnancy. Marks PW Semin Perinatol; 2007 Aug; 31(4):227-31. PubMed ID: 17825678 [TBL] [Abstract][Full Text] [Related]
5. [heparin and insulin treatment of acute pancreatitis caused by hypertriglyceridemia. Experience of 5 cases]. Berger Z; Quera R; Poniachik J; Oksenberg D; Guerrero J Rev Med Chil; 2001 Dec; 129(12):1373-8. PubMed ID: 12080874 [TBL] [Abstract][Full Text] [Related]
6. The status of new anticoagulants. Bates SM; Weitz JI Br J Haematol; 2006 Jul; 134(1):3-19. PubMed ID: 16803562 [TBL] [Abstract][Full Text] [Related]
7. Low-molecular-weight heparin for initial treatment of venous thromboembolism. Brewer D Am Fam Physician; 2005 Jul; 72(1):75-6. PubMed ID: 16035683 [No Abstract] [Full Text] [Related]
8. [Possible effect low molecular weight heparin on survival time. New chances for cancer patients?]. MMW Fortschr Med; 2003 May; 145(19):suppl 3-4. PubMed ID: 12813994 [No Abstract] [Full Text] [Related]
9. The battle of the clot. Mandell BF Cleve Clin J Med; 2009 Feb; 76(2):80. PubMed ID: 19188470 [No Abstract] [Full Text] [Related]
10. The optimal long-term treatment of venous thromboembolism. Prandoni P Clin Adv Hematol Oncol; 2004 Nov; 2(11):729-32. PubMed ID: 16170889 [No Abstract] [Full Text] [Related]
11. [Natural and synthetic glycosaminoglycans. Molecular characteristics as the basis of distinct drug profiles]. Alban S Hamostaseologie; 2008 Feb; 28(1-2):51-61. PubMed ID: 18278163 [TBL] [Abstract][Full Text] [Related]
12. Effect of obesity on outcomes after fondaparinux, enoxaparin, or heparin treatment for acute venous thromboembolism in the Matisse trials. Davidson BL; Büller HR; Decousus H; Gallus A; Gent M; Piovella F; Prins MH; Raskob GE; Segers AE; Lensing AW; J Thromb Haemost; 2007 Jun; 5(6):1191-4. PubMed ID: 17403087 [TBL] [Abstract][Full Text] [Related]
13. Low-molecular-weight heparin in oncology. Zacharski LR; Loynes JT Anticancer Res; 2003; 23(3C):2789-93. PubMed ID: 12926114 [TBL] [Abstract][Full Text] [Related]